1. Home
  2. AMWD vs SPRY Comparison

AMWD vs SPRY Comparison

Compare AMWD & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo American Woodmark Corporation

AMWD

American Woodmark Corporation

HOLD

Current Price

$35.80

Market Cap

872.8M

ML Signal

HOLD

Logo ARS Pharmaceuticals Inc.

SPRY

ARS Pharmaceuticals Inc.

HOLD

Current Price

$7.77

Market Cap

823.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMWD
SPRY
Founded
1980
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Forest Products
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
872.8M
823.2M
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
AMWD
SPRY
Price
$35.80
$7.77
Analyst Decision
Buy
Strong Buy
Analyst Count
2
1
Target Price
$59.50
$40.00
AVG Volume (30 Days)
234.2K
1.8M
Earning Date
05-28-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,709,585,000.00
$84,278,000.00
Revenue This Year
N/A
$87.40
Revenue Next Year
N/A
$81.64
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$33.29
$6.66
52 Week High
$72.16
$18.63

Technical Indicators

Market Signals
Indicator
AMWD
SPRY
Relative Strength Index (RSI) 37.41 44.65
Support Level N/A $6.93
Resistance Level $42.58 $8.61
Average True Range (ATR) 2.03 0.54
MACD -0.46 -0.13
Stochastic Oscillator 22.99 30.51

Price Performance

Historical Comparison
AMWD
SPRY

About AMWD American Woodmark Corporation

American Woodmark Corp manufactures and distributes cabinets and vanities for the remodeling and new home construction markets. It offers several products that fall into product lines including kitchen cabinetry, bath cabinetry, office cabinetry, home organization, and hardware. The products are sold under the brand names American Woodmark, Timberlake, Shenandoah Cabinetry, and Waypoint Living Spaces among others.

About SPRY ARS Pharmaceuticals Inc.

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.

Share on Social Networks: